Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia

Yuko Nakanishi, Koichi Tsuneyama, Makoto Fujimoto, Thucydides L. Salunga, Kazuhiro Nomoto, Jun Ling An, Yasuo Takano, Seiichi Iizuka, Mitsunobu Nagata, Wataru Suzuki, Tsutomu Shimada, Masaki Aburada, Masayuki Nakano, Carlo Selmi, M. Eric Gershwin

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Chronic inflammation is a common theme in a variety of disease pathways, including autoimmune diseases. The pathways of chronic inflammation are well illustrated by nonalcoholic steatohepatitis (NASH), which is of a serious concern due to its increasing prevalence in the westernized world and its direct correlation with lifestyle factors, particularly diet. Importantly, NASH may ultimately lead to the development of hepatocellular carcinoma. We previously reported that injection of monosodium glutamate (MSG) in ICR mice leads to the development of significant inflammation, central obesity, and type 2 diabetes. To directly address the long-term consequences of MSG on inflammation, we have performed serial analysis of MSG-injected mice and focused in particular on liver pathology. By 6 and 12 months of age, all MSG-treated mice developed NAFLD and NASH-like histology, respectively. In particular, the murine steatohepatitis at 12 months was virtually undistinguishable from human NASH. Further, dysplastic nodular lesions were detected in some cases within the fibrotic liver parenchyma. We submit that MSG treatment of mice induces obesity and diabetes with steatosis and steatohepatitis resembling human NAFLD and NASH with pre-neoplastic lesions. These results take on considerable significance in light of the widespread usage of dietary MSG and we suggest that MSG should have its safety profile re-examined and be potentially withdrawn from the food chain.

Original languageEnglish (US)
Pages (from-to)42-50
Number of pages9
JournalJournal of Autoimmunity
Volume30
Issue number1-2
DOIs
StatePublished - Feb 2008

Fingerprint

Sodium Glutamate
Inflammation
Liver
Fatty Liver
Inbred ICR Mouse
Food Chain
Abdominal Obesity
Non-alcoholic Fatty Liver Disease
Type 2 Diabetes Mellitus
Autoimmune Diseases
Life Style
Hepatocellular Carcinoma
Histology
Obesity
Pathology
Diet
Safety
Injections

Keywords

  • Diabetes mellitus
  • Liver steatosis
  • Nonalcoholic steatohepatitis
  • Obesity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Monosodium glutamate (MSG) : A villain and promoter of liver inflammation and dysplasia. / Nakanishi, Yuko; Tsuneyama, Koichi; Fujimoto, Makoto; Salunga, Thucydides L.; Nomoto, Kazuhiro; An, Jun Ling; Takano, Yasuo; Iizuka, Seiichi; Nagata, Mitsunobu; Suzuki, Wataru; Shimada, Tsutomu; Aburada, Masaki; Nakano, Masayuki; Selmi, Carlo; Gershwin, M. Eric.

In: Journal of Autoimmunity, Vol. 30, No. 1-2, 02.2008, p. 42-50.

Research output: Contribution to journalArticle

Nakanishi, Y, Tsuneyama, K, Fujimoto, M, Salunga, TL, Nomoto, K, An, JL, Takano, Y, Iizuka, S, Nagata, M, Suzuki, W, Shimada, T, Aburada, M, Nakano, M, Selmi, C & Gershwin, ME 2008, 'Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia', Journal of Autoimmunity, vol. 30, no. 1-2, pp. 42-50. https://doi.org/10.1016/j.jaut.2007.11.016
Nakanishi Y, Tsuneyama K, Fujimoto M, Salunga TL, Nomoto K, An JL et al. Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia. Journal of Autoimmunity. 2008 Feb;30(1-2):42-50. https://doi.org/10.1016/j.jaut.2007.11.016
Nakanishi, Yuko ; Tsuneyama, Koichi ; Fujimoto, Makoto ; Salunga, Thucydides L. ; Nomoto, Kazuhiro ; An, Jun Ling ; Takano, Yasuo ; Iizuka, Seiichi ; Nagata, Mitsunobu ; Suzuki, Wataru ; Shimada, Tsutomu ; Aburada, Masaki ; Nakano, Masayuki ; Selmi, Carlo ; Gershwin, M. Eric. / Monosodium glutamate (MSG) : A villain and promoter of liver inflammation and dysplasia. In: Journal of Autoimmunity. 2008 ; Vol. 30, No. 1-2. pp. 42-50.
@article{951a6e46ad6b4d09af6b898489f3c4a7,
title = "Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia",
abstract = "Chronic inflammation is a common theme in a variety of disease pathways, including autoimmune diseases. The pathways of chronic inflammation are well illustrated by nonalcoholic steatohepatitis (NASH), which is of a serious concern due to its increasing prevalence in the westernized world and its direct correlation with lifestyle factors, particularly diet. Importantly, NASH may ultimately lead to the development of hepatocellular carcinoma. We previously reported that injection of monosodium glutamate (MSG) in ICR mice leads to the development of significant inflammation, central obesity, and type 2 diabetes. To directly address the long-term consequences of MSG on inflammation, we have performed serial analysis of MSG-injected mice and focused in particular on liver pathology. By 6 and 12 months of age, all MSG-treated mice developed NAFLD and NASH-like histology, respectively. In particular, the murine steatohepatitis at 12 months was virtually undistinguishable from human NASH. Further, dysplastic nodular lesions were detected in some cases within the fibrotic liver parenchyma. We submit that MSG treatment of mice induces obesity and diabetes with steatosis and steatohepatitis resembling human NAFLD and NASH with pre-neoplastic lesions. These results take on considerable significance in light of the widespread usage of dietary MSG and we suggest that MSG should have its safety profile re-examined and be potentially withdrawn from the food chain.",
keywords = "Diabetes mellitus, Liver steatosis, Nonalcoholic steatohepatitis, Obesity",
author = "Yuko Nakanishi and Koichi Tsuneyama and Makoto Fujimoto and Salunga, {Thucydides L.} and Kazuhiro Nomoto and An, {Jun Ling} and Yasuo Takano and Seiichi Iizuka and Mitsunobu Nagata and Wataru Suzuki and Tsutomu Shimada and Masaki Aburada and Masayuki Nakano and Carlo Selmi and Gershwin, {M. Eric}",
year = "2008",
month = "2",
doi = "10.1016/j.jaut.2007.11.016",
language = "English (US)",
volume = "30",
pages = "42--50",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Monosodium glutamate (MSG)

T2 - A villain and promoter of liver inflammation and dysplasia

AU - Nakanishi, Yuko

AU - Tsuneyama, Koichi

AU - Fujimoto, Makoto

AU - Salunga, Thucydides L.

AU - Nomoto, Kazuhiro

AU - An, Jun Ling

AU - Takano, Yasuo

AU - Iizuka, Seiichi

AU - Nagata, Mitsunobu

AU - Suzuki, Wataru

AU - Shimada, Tsutomu

AU - Aburada, Masaki

AU - Nakano, Masayuki

AU - Selmi, Carlo

AU - Gershwin, M. Eric

PY - 2008/2

Y1 - 2008/2

N2 - Chronic inflammation is a common theme in a variety of disease pathways, including autoimmune diseases. The pathways of chronic inflammation are well illustrated by nonalcoholic steatohepatitis (NASH), which is of a serious concern due to its increasing prevalence in the westernized world and its direct correlation with lifestyle factors, particularly diet. Importantly, NASH may ultimately lead to the development of hepatocellular carcinoma. We previously reported that injection of monosodium glutamate (MSG) in ICR mice leads to the development of significant inflammation, central obesity, and type 2 diabetes. To directly address the long-term consequences of MSG on inflammation, we have performed serial analysis of MSG-injected mice and focused in particular on liver pathology. By 6 and 12 months of age, all MSG-treated mice developed NAFLD and NASH-like histology, respectively. In particular, the murine steatohepatitis at 12 months was virtually undistinguishable from human NASH. Further, dysplastic nodular lesions were detected in some cases within the fibrotic liver parenchyma. We submit that MSG treatment of mice induces obesity and diabetes with steatosis and steatohepatitis resembling human NAFLD and NASH with pre-neoplastic lesions. These results take on considerable significance in light of the widespread usage of dietary MSG and we suggest that MSG should have its safety profile re-examined and be potentially withdrawn from the food chain.

AB - Chronic inflammation is a common theme in a variety of disease pathways, including autoimmune diseases. The pathways of chronic inflammation are well illustrated by nonalcoholic steatohepatitis (NASH), which is of a serious concern due to its increasing prevalence in the westernized world and its direct correlation with lifestyle factors, particularly diet. Importantly, NASH may ultimately lead to the development of hepatocellular carcinoma. We previously reported that injection of monosodium glutamate (MSG) in ICR mice leads to the development of significant inflammation, central obesity, and type 2 diabetes. To directly address the long-term consequences of MSG on inflammation, we have performed serial analysis of MSG-injected mice and focused in particular on liver pathology. By 6 and 12 months of age, all MSG-treated mice developed NAFLD and NASH-like histology, respectively. In particular, the murine steatohepatitis at 12 months was virtually undistinguishable from human NASH. Further, dysplastic nodular lesions were detected in some cases within the fibrotic liver parenchyma. We submit that MSG treatment of mice induces obesity and diabetes with steatosis and steatohepatitis resembling human NAFLD and NASH with pre-neoplastic lesions. These results take on considerable significance in light of the widespread usage of dietary MSG and we suggest that MSG should have its safety profile re-examined and be potentially withdrawn from the food chain.

KW - Diabetes mellitus

KW - Liver steatosis

KW - Nonalcoholic steatohepatitis

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=38049028313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049028313&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2007.11.016

DO - 10.1016/j.jaut.2007.11.016

M3 - Article

C2 - 18178378

AN - SCOPUS:38049028313

VL - 30

SP - 42

EP - 50

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 1-2

ER -